Marijuana-based drugs: Innovative therapeutics or designer drugs of abuse?

Molecular Interventions

Volumn 11, Issue 1, 2011, Pages 36-51

  Seely, Kathryn A ^a   Prather, Paul L ^a   James, Laura P ^b   Moran, Jeffery H ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c ARKANSAS DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; AM 4113; ANANDAMIDE; ANTINEOPLASTIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABIS; CP 47 497; CP 50 556 1; CP 55 940; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ESTERASE INHIBITOR; JWH 073; JZL 184; LEVONANTRADOL; NABILONE; ORG 27569; PRAVADOLINE; PSNCBAM 1; RIMONABANT; SAB 378; SAN 378; TARANABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 447; WIN 48 098; WIN 55 212 2;

APPETITE; ATHEROMA; ATHEROSCLEROSIS; BEHAVIOR CHANGE; CANCER PAIN; CANNABIS ADDICTION; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG INTOXICATION; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; HISTORY; HUMAN; INFLAMMATION; LIVER FIBROSIS; MEDICINAL PLANT; MEMORY DISORDER; METABOLIC SYNDROME X; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PSYCHOMOTOR PERFORMANCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SIDE EFFECT; SUICIDAL IDEATION; UNITED STATES; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANIMALS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS AS TOPIC; DESIGNER DRUGS; HUMANS; MODELS, BIOLOGICAL; STREET DRUGS;

EID: 79953228493     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.11.1.6     Document Type: Review

References (126)

1. Zuardi AW (2006) History of cannabis as a medicine: a review. Rev Bras Psiquiatr 28:153-157.
2. Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, and Namaka M (2010) Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Investig Drugs 11:17-31.
3. Vardakou I, Pistos C, and Spiliopoulou C (2010) Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197:157-162.
4. Guindon J and Hohmann AG (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334.
5. Touw M (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 13:23-34.
6. Musto DF (1972) The Marihuana Tax Act of 1937. Arch Gen Psychiatry 26:101-108.
7. Banken JA (2004) Drug abuse trends among youth in the United States. Ann NY Acad Sci 1025:465-471.
8. Gaoni Y and Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647. This study was the first to isolate and identify Δ9-THC from cannabis.
9. Di Marzo V (2006) A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci 27:134-140.
10. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613. This was the initial study to report the identification of CB1Rs in brain.
11. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
12. Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20 Suppl 1:10-14.
13. Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589. (Pubitemid 40594198)
14. Randall MD, Kendall DA, and O'Sullivan S (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142:20-26. (Pubitemid 38698188)
15. Eggan SM and Lewis DA (2007) Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17:175-191. (Pubitemid 44973906)
16. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, and Porrino LJ (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 Suppl 1:345-358. (Pubitemid 39298276)
17. Munro S, Thomas K, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. These authors were the first to clone CB2Rs from immune cells.
18. Atwood BK and Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479.
19. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
20. Shoemaker JL, Seely KA, Reed RL, Crow JP, and Prather PL (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101:87-98. (Pubitemid 46426470)
21. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-436.
22. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62:588-631.
23. Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, and Elsohly MA (2009) Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat CNS Drug Discov 4:112-136.
24. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949. This study reported the isolation and identification of anadamide (AEA) as the first endocannabinoid.
25. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, and et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90. These authors were one of two groups to first identify 2AG as a second endocannabinoid.
26. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97. This study was one of two that initially reported the characterization of 2AG as a second cannabinoid.
27. Mackie K, Devane WA, and Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44:498-503. (Pubitemid 23280258)
28. Griffin G, Tao Q, and Abood ME (2000) Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292:886-894. (Pubitemid 30136579)
29. Stella N, Schweitzer P, and Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778. (Pubitemid 27375156)
30. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, and Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045-1050. (Pubitemid 30253390)
31. De Petrocellis L, Cascio MG, and Di Marzo V (2004) The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774. (Pubitemid 38446177)
32. Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discovery 7:438-455.
33. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122.
34. Di Marzo V (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60:77-84.
35. Little PJ, Compton DR, Johnson MR, Melvin LS, and Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247:1046-1051. This article details a "tetrad" of animal behaviors routinely used to quantify the actions of cannabinoid CB1R agonsts.
36. Hall W and Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383-1391.
37. Williams CM, Rogers PJ, and Kirkham TC (1998) Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 65:343-346. (Pubitemid 28548657)
38. Vemuri VK, Janero DR, and Makriyannis A (2008) Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 93:671-686. (Pubitemid 351410420)
39. Rodriguez JJ, Mackie K, and Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21:823-833. (Pubitemid 32163123)
40. Sim LJ, Hampson RE, Deadwyler SA, and Childers SR (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:8057-8066. (Pubitemid 26405066)
41. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, and Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123-1131. (Pubitemid 34252081)
42. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, and Van Os J (2004) Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99:1333-1341. (Pubitemid 39330938)
43. Klein T, Newton C, Larsen K, Lu L, Perkins I, Liang N, and Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496. (Pubitemid 38040375)
44. Graham ES, Ashton JC, and Glass M (2009) Cannabinoid receptors: a brief history and "what's hot." Front Biosci 14:944-957.
45. Pertwee RG and Thomas A (2009) Therapeutic applications for agents that act at CB1 and CB2 receptors, in The Cannabinoid Receptors (Reggio, PH ed), pp 361-392, Humana Press, Totowa.
46. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397-411.
47. Lee HK, Choi EB, and Pak CS (2009) The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as antiobesity agents. Curr Top Med Chem 9:482-503.
48. Janero DR and Makriyannis A (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14:43-65.
49. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, and Mayer JD (2009) Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 5:153-168.
50. Moreira FA, Grieb M, and Lutz B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133-144.
51. Jones D (2008) End of the line for cannabinoid receptor 1 as an antiobesity target? Nat Rev Drug Discovery 7:961-962. This article reviews both the positive and negative effects encountered during the clinical trials of the CB1 inverse agonist rimonabant.
52. Einhorn LH, Nagy C, Furnas B, and Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21:64S-69S.
53. Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, and Jamison K (1985) THC or Compazine for the cancer chemotherapy patient--the UCLA study. Part II: Patient drug preference. Am J Clin Oncol 8:142-147. (Pubitemid 15242282)
54. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, and Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831. (Pubitemid 23225663)
55. Smith PF (2004) GW-1000. GW Pharmaceuticals. Curr Opin Investig. Drugs 5:748-754.
56. Barnes MP (2006) Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 7:607-615.
57. Russo E and Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234-246. (Pubitemid 41773895)
58. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, and Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555.
59. Corica F, Corsonello A, Apolone G, Mannucci E, Lucchetti M, Bonfiglio C, Melchionda N, and Marchesini G (2008) Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. Int J Obes 32:185-191.
60. Robinson JR and Niswender KD (2009) What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 9:368-375.
61. Oh S, Kim KS, Chung YS, Shong M, and Park SB (2009) Anti-obesity agents: a focused review on the structural classification of therapeutic entities. Curr Top Med Chem 9:466-481.
62. Engeli S (2008) Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 20 Suppl 1:110-115.
63. Jesudason D and Wittert G (2008) Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 19:344-348.
64. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, and Stumvoll M (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-3060. (Pubitemid 44923642)
65. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, Macias M, Goya P, and de Fonseca FR (2008) Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20 Suppl 1:116-123. This study was one of the first to provide data indicating that many of the anti-obesity effects of CB1 inverse agonists may be mediated via CB1Rs located outside the CNS.
66. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, et al. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
67. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, and Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl 2:S229-S240.
68. Rosenstock J, Hollander P, Chevalier S, and Iranmanesh A (2008) SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31:2169-2176.
69. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299:1547-1560. (Pubitemid 351482794)
70. Christensen R, Kristensen PK, Bartels EM, Bliddal H, and Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet 370:1706-1713. (Pubitemid 350100788)
71. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, and Hohmann AG (2007) Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150:153-163. (Pubitemid 46160605)
72. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu C, Tarzia G, and Piomelli D (2009) Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 19:639-643.
73. Cluny NL, Keenan CM, Duncan M, Fox A, Lutz B, and Sharkey KA (2010) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 334:973-980.
74. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495. This study characterized the first class of allosteric modulators to be identified for CB1Rs.
75. Wang L, Martin B, Brenneman R, Luttrell LM, and Maudsley S (2009) Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331:340-348.
76. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, et al. (2010) Ligandspecific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463:108-112.
77. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, and Wong Kai In P (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152:805-814. These authors identified a second class of CB1R allosteric modulators that not only produce allosteric modulation in vitro, but also decrease appetite in animals.
78. Wang X, Horswill JG, Whalley BJ, and Stephens GJ (2010) Effects of the allosteric antagonist PSNCBAM-1 on CB1 receptor modulation in the cerebellum. Mol Pharmacol doi: 10.1124/mol.110.068197
79. Di Marzo V and Petrosino S (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18:129-140. This extensive review article summarizes current evidence suggesting that endocannabinoids may exert either beneficial or harmful effects, depending on a complex number of disease-specific variables.
80. Cravatt BF and Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475. (Pubitemid 36980837)
81. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, and Lichtman AH (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther. 334:182-90.
82. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119.
83. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, and Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-298.
84. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman, AH, et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
85. Ligresti A, De Petrocellis L, Hernan Perez de la Ossa D, Aberturas R, Cristino L, Moriello AS, Finizio A, Gil ME, Torres AI, Molpeceres J, et al. (2010) Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter. PLoS One 5:e10239.
86. Canals M and Milligan G (2008) Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 283:11424-11434.
87. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
88. Muccioli GG (2007) Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem Biodivers 4:1805-1827.
89. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, and Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193. (Pubitemid 350224010)
90. Bermudez-Silva FJ, Viveros MP, McPartland JM, and Rodriguez de Fonseca F (2010) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95:375-382.
91. Iversen LL (2008) The Science of Marijuana, 2nd ed. Oxford University Press, Inc., New York.
92. Budzikiewicz H, Alpin RT, Lightner DA, Djerassi C, Mechoulam R, and Gaoni Y (1965) Mass spectroscopy and its application to structural and stereochemical problems. 68. Mass spectroscopic studies of constituents of hashish. Tetrahedron 21:1881-1888.
93. Mechoulam R and Gaoni Y (1965) A total synthesis of Dl-Delta-1- Tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273-3275.
94. Mechoulam R and Gaoni Y (1965) Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21:1223-1229.
95. Mechoulam R, Braun P, and Gaoni Y (1967) A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc 89:4552-4554.
96. Mechoulam R and Gaoni Y (1967) The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12:1109-1111.
97. Mechoulam R and Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25:175-213.
98. Huffman JW (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions, in The Cannabinoid Receptors, The Receptors, part I(Reggio, PH ed), pp49-94, Humana Press, Totowa.
99. Shim JY, Welsh WJ, and Howlett AC (2003) Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 71:169-189. (Pubitemid 36702318)
100. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, and Haycock DA (1993) Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 264:1352-1363. (Pubitemid 23318632)
101. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, and Martin BR (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004.
102. EMCDDA (2009) Understanding the 'Spice' phenomenon. European Monitoring Centre for Drugs and Drug Addiction EMCDDA 2009 Thematic paper Ed., Office for Official Publications of the European Communities
103. Chin CN, Murphy JW, Huffman JW, and Kendall DA (1999) The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther 291:837-844. (Pubitemid 29503560)
104. Showalter VM, Compton DR, Martin BR, and Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999. (Pubitemid 27166944)
105. Compton DR, Gold LH, Ward SJ, Balster RL, and Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126. (Pubitemid 23157189)
106. Compton DR, Johnson MR, Melvin LS, and Martin BR (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
107. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226. (Pubitemid 23320964)
108. Huffman JW, Padgett LW, Isherwood ML, Wiley JL, and Martin BR (2006) 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett 16:5432-5435. (Pubitemid 44332197)
109. Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, and Martin BR (2005) 1-Pentyl-3- phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110-4113. (Pubitemid 41132671)
110. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann JL Jr., Wetzel JR, Rosi D, Philion RE, Daum SJ, Hlasta DJ, et al. (1991) Antinociceptive (aminoalkyl)indoles. J Med Chem 34:1099-1110.
111. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM, et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 38:3094-3105.
112. Weissman A, Milne GM, and Melvin LS Jr (1982) Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516-523. (Pubitemid 12005757)
113. Pacheco M, Childers SR, Arnold R, Casiano F, and Ward SJ (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 257:170-183.
114. Whalen J (2010) In quest for "legal high," chemists outfox law. in Wall Street Journal, October 30, - http://online.wsj.com/article/SB100014240 52748704763904575550200845267526.html. This Wall Street Journal article details the successful strategies often employed by street chemists to evade detection of illegal substances by coventional drug screens by employing synthetic marijuana compounds.
115. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, and Wood DM (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 34:252-260.
116. Piggee C (2009) Investigating a not-so-natural high. Anal Chem 81:3205-3207.
117. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, and Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 57:439-441.
118. Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, and Auwarter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186-1194.
119. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, and Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58-63.
120. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, and Ferreiros N (2009) 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832-837.
121. Schneir AB, Cullen J, and Ly BT (2010) "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med doi:10.1016/j.jemermed.2010.10.014
122. Every-Palmer S (2010) Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 105:1859-1860. This study was one of the first to show that synthetic cannabinoids contained in K2 produce adverse effects not normally associated with traditional cannabis use.
123. Vearrier D and Osterhoudt KC (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26:462-465.
124. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, and Maler JM (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118:309-310.
125. Gay M (2010) Synthetic marijuana spurs state bans. in The New York Times, July 10, http://www.nytimes.com/2010/07/11/us/11k2.html.
126. Fisher WG (2010) Inhaled incense "K2" may cause heart damage. in Musings in the Life of an Internist, Cardioloist and Cardiac Electrophysiologist, August 15, http://drwes.blogspot.com/2010/08/ inhaled-incense-k2-may-cause-heart.html? The information provided in this blog from a cardiologist provides the first documented case suggesting K2 use, in some instances, may be fatal.